I figure it should be a big number, considering that ACXP's drug will likely become the new standard treatment for C. Dif, and the market is so huge --> 500,000 cases of C. Dif in the US per year, and 20,000 deaths. So the acquisition price tag can be many multiples of ACXP's current $75 mil market cap. We should get the full unblinded Phase 2b details soon, although we already know that clinically the results were excellent. While the bio sector is full of surprises, logic says that ACXP should be a big winner, so we'll see what happens :o)
---
Recent ACXP News
- New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET • GlobeNewswire Inc. • 08/09/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 11:13:16 AM
- Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update • PR Newswire (US) • 08/09/2024 11:01:00 AM
- USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome • PR Newswire (US) • 07/17/2024 11:00:00 AM
- Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update • PR Newswire (US) • 07/16/2024 11:00:00 AM
- Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference • PR Newswire (US) • 07/15/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:14:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:11:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:14:40 PM
- New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PT • GlobeNewswire Inc. • 06/06/2024 01:30:00 PM
- Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection • PR Newswire (US) • 05/15/2024 01:00:00 PM
- U.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices Drop • IH Market News • 05/15/2024 11:50:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:13:05 AM
- Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update • PR Newswire (US) • 05/15/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:05:29 PM
- Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference • PR Newswire (US) • 05/02/2024 11:00:00 AM
- Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference • PR Newswire (US) • 04/25/2024 02:12:00 PM
- Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update • PR Newswire (US) • 04/23/2024 02:57:00 PM
- Unilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and More • IH Market News • 03/19/2024 11:33:10 AM
- Anticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See Upticks • IH Market News • 03/18/2024 11:12:12 AM
- Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update • PR Newswire (US) • 03/18/2024 11:01:00 AM
- Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update • PR Newswire (US) • 03/04/2024 12:01:00 PM
- Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development • PR Newswire (US) • 02/27/2024 12:01:00 PM
- New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series • GlobeNewswire Inc. • 02/23/2024 02:30:00 PM
- New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT • GlobeNewswire Inc. • 02/16/2024 02:30:00 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM